Demonstrating Operational Agility: FutureMeds Delivers First Global Randomisation in Complex Insomnia Trial

How cross-site collaboration and operational excellence enabled FutureMeds Wroclaw to deliver its first-ever sleep study and achieve the first global randomisation in this complex trial. 

On June 17, 2025, our Wroclaw site reached a significant milestone: the first patient randomised globally in a multinational insomnia trial. Beyond marking a procedural achievement, this milestone demonstrates FutureMeds’ ability to rapidly build new therapeutic capabilities, adapt operationally, and deliver high-value solutions for our partners. 

For patients suffering from insomnia, often grappling with fatigue, mood disturbances, and diminished quality of life, the trial offers hope for new treatment options.

" I decided to participate in the clinical trial because insomnia significantly reduces my quality of life. I had major concerns before joining the study, but the staff at the site explained everything to me thoroughly and showed great empathy, which significantly reduced my anxiety about starting this project. I am very satisfied with the medical care provided at the site. The staff is very friendly and professional." 

— Insomnia Study Participant 

Rapid Capability Expansion: From Concept to Sleep Lab 

For the dedicated team of FutureMeds Wroclaw, this was a first in many ways. The site had no prior experience in sleep research and had to meet significant demands set out by the protocol: patients at the site would undergo overnight polysomnography (PSG), continuous ECG recording, and multiple blood draws, all requiring precision and patient comfort over multiple overnight stays. 

The easiest step was transforming a standard medical room into a fully equipped sleep laboratory. This meant fitting blackout curtains, soundproofing, and clinical-grade equipment. By applying wallpaper, the team also aimed to create an atmosphere that felt welcoming and calming for patients spending extended hours on-site. As one participant described: "In the room where I slept, I felt at home. Even the colour of the bedding matched the walls." 

One of the key hurdles was the capability gap. That's where FutureMeds' model, the power of our network and our culture's emphasis on people, access, collaboration and truth came into full play. 

While Wroclaw was new to sleep research, our Berlin team’s deep expertise in the field unlocked the option of rapid knowledge and procedural transfer through a series of intensive training sessions, ongoing mentoring, and close digital collaboration.  

Christoph Mende, an experienced Polysomnography technician from Berlin, conducted 2-day on-site sessions to train staff in the complex procedures, while daily coordination between project teams ensured smooth study initiation. 

"The Berlin team’s experience was invaluable," commented Martyna Walasek, Associate Project Manager. "They shared practical insights on everything from PSG procedures to optimising patient visit flows." 

Precision Meets Compassion 

Executing this protocol requires attention to detail, effective communication and focus on patient experience starting with recruitment.  

“Every day, we see how deeply insomnia affects patients’ lives. For this study, it was crucial not only to reach eligible patients, but also to find those willing and able to commit to the intensive qualification process. By leveraging advanced digital recruitment tools and working hand-in-hand with our research team our Patient Engagement team in Germany we built an effective outreach campaign that has the potential to accelerate access to innovative insomnia treatments for patients worldwide,” commented Arkadiusz Kasperski, Head of Patient Engagement at FutureMeds Poland. 

After randomisation, each overnight visit involves applying 42 sensors per patient, maximum 8 blood draws. With some visits extending up to 18 hours, teamwork and mutual support are critical success factors. 

“In our view, the success of the study hinges on two main factors. Effective communication among all stakeholders, including the coordinating team, polysomnography technicians, nursing staff, and physicians. And patient comfort, which was always a priority. We provided thorough pre-visit education, onsite amenities, and a personalised, empathetic approach throughout,” added Aleksandra Wolny, Head of Nurse Team at FutureMeds Wroclaw

The Power of the Network

The first global randomisation in this study is a proud moment for FutureMeds Wroclaw and the entire FutureMeds network. It demonstrates our ability to rapidly build operational capability in new therapeutic areas, invest in site readiness, and deliver for sponsors even in highly complex protocols. 

"This achievement reinforces our clients’ confidence in FutureMeds’ ability to expand into new therapeutic areas. Our teams have demonstrated the operational strength and flexibility needed to deliver complex protocols. Most importantly, it allows us to broaden patient access to high-quality care and innovative treatment options." 

— Wojciech Szczepanik PhD, executive VP of Site Operations 

As FutureMeds continues to grow, we remain committed to operational precision, cross-site collaboration, and patient-centred care, delivering world-class research for our partners and hope for patients.